Hoyos Rocio Martin 4

What Happened

• Rocio Hoyos Martin, Chief Strategy Officer of Atrium Therapeutics (RNA), received equity awards on April 20, 2026: 30,000 restricted stock units (RSUs) and 60,000 derivative awards (stock option-style), each granted at $0.00 (no cash exchanged). These are compensation grants, not open-market purchases or sales.

Key Details

• Transaction date: 2026-04-20; Form 4 filed 2026-04-22 (appears timely).
• Award amounts and price: 30,000 RSUs @ $0.00; 60,000 derivative awards (options) @ $0.00.
• Shares owned after transaction: Not reported in this filing.
• Vesting (from footnotes):
  • RSUs (30,000): 25% vest on March 20, 2027; remaining RSUs vest in three substantially equal annual installments thereafter (subject to continued service).
  • Derivative awards/options (60,000): 25% vest on March 20, 2027; remaining shares vest in 36 substantially equal monthly installments thereafter (subject to continued service).
• No 10b5-1 plan, tax-withholding, or late-filing flag disclosed in this filing.

Context

• RSUs: each RSU is a contingent right to receive one share upon vesting (no immediate shares received).
• Derivative awards/options: represent the right to acquire shares if/when vested and exercised; they are not the same as owning shares today.
• These grants are typical executive compensation and do not by themselves indicate a buying or selling decision in the open market.